2007
DOI: 10.1530/eje-07-0242
|View full text |Cite
|
Sign up to set email alerts
|

Clinical and biological phenotype of a patient with familial glucocorticoid deficiency type 2 caused by a mutation of melanocortin 2 receptor accessory protein

Abstract: Familial glucocorticoid deficiency (FGD) is a rare inherited disorder which may be caused by mutations in the ACTH receptor (melanocortin 2 receptor, MC2R) named FGD type 1 or by mutations in the MC2R accessory protein (MRAP) named FGD type 2. We report the case history of a male patient from birth until adulthood with FGD type 2, confirmed by a mutation of the MRAP gene.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
13
0

Year Published

2009
2009
2022
2022

Publication Types

Select...
7
3

Relationship

2
8

Authors

Journals

citations
Cited by 21 publications
(14 citation statements)
references
References 13 publications
1
13
0
Order By: Relevance
“…This is probably consistent with the short stature of his parents. Early onset obesity has also been reported in one family with MRAP mutation (16), this is not a feature noted in our patient.…”
Section: Discussionsupporting
confidence: 71%
“…This is probably consistent with the short stature of his parents. Early onset obesity has also been reported in one family with MRAP mutation (16), this is not a feature noted in our patient.…”
Section: Discussionsupporting
confidence: 71%
“…As an essential component for MC2R function, MRAP was first identified by Clark and colleagues in 2004 (Metherell et al 2004). Its mutation has been shown to be responsible for some cases of familial glucocorticoid deficiency type 2, in which there is elevated ACTH but low or absent circulating cortisol (Metherell et al 2005; Rumie et al 2007). By stimulating expression of both MC2R and MRAP concomitantly, ACTH forms a feed forward loop leading to amplification of responsiveness.…”
Section: Discussionmentioning
confidence: 99%
“…Although both MRAPs reduce MC3R signalling, it is more likely that MRAP2 regulates MC3R in vivo as both are mostly expressed in the hypothalamus. With the exception of one family, altered body weight has not been observed in patients with MRAP mutations, suggesting that MRAP may not be the key hypothalamic player (Rumie et al 2007). However, this does not exclude the possibility of MC3R regulation by MRAP in other tissues where MC3R is also expressed such as in adipose tissue, heart (Chagnon et al 1997), skeletal muscle, kidney (Chhajlani 1996), stomach, duodenum, placenta, pancreas (Gantz et al 1993) and immunocompetent cells (Getting et al 1999, Lindberg et al 2005.…”
Section: Mrap and Mrap2 Function Beyond The Adrenal Glandmentioning
confidence: 99%